Diabetes Discourse
The prevalence of type 2 diabetes has increased to more than 8% of the US population, and this growth trend is expected to continue. Advances in diabetes care remain at the forefront of treatment. Diabetes Discourse features the latest developments, from new insulin therapies to exciting research and promising technology.
- Website
- http://reachmd.com/programs/diabetes-discourse/
- Description
- The prevalence of type 2 diabetes has increased to more than 8% of the US population, and this growth trend is expected to continue. Advances in diabetes care remain at the forefront of treatment. Diabetes Discourse features the latest developments, from new insulin therapies to exciting research and promising technology.
- Language
- 🇬🇧 English
- last modified
- 2024-12-21 02:53
- last episode published
- 2024-05-21 00:00
- publication frequency
- 11.28 days
- Contributors
- ReachMD
- Owner Author
- Explicit
- false
- Number of Episodes
- 486
- Rss-Feeds
- Detail page
- Categories
- Medicine Science & Medicine Health & Fitness
Recommendations
Episodes
| Date | Title & Description | Contributors |
|---|---|---|
| 2024-05-21 | Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Ian de Boer, MD Since up to 40 percent of patients with diabetes develop diabetic kidney disease, it’s essential to know how to proactively diagnose and treat them using the lat... | |
| 2024-05-09 |
Uncovering the Prevalence of Type 1 Diabetes in Older Adults Guest: Elena Toschi, MD Approximately over the last decade, lifespans in the general population have increased, along with a rise in the prevalence of type 1 diabetes in older adult patients. Since each patient has a unique disease, the clini... |
|
| 2024-05-09 |
Uncovering the Prevalence of Type 1 Diabetes in Older Adults Guest: Elena Toschi, MD Approximately over the last decade, lifespans in the general population have increased, along with a rise in the prevalence of type 1 diabetes in older adult patients. Since each patient has a unique disease, the clini... |
|
| 2024-04-12 |
Concentrating on the MOMPOD Trial for Metformin Plus Insulin Host: John Buse, MD, PhD Guest: Kim Boggess, MD The most common forms of diabetes encountered in pregnant patients include gestational diabetes and preexisting type 2 diabetes. So how does adding metformin to insulin treatment help these ... |
|
| 2024-04-12 |
Concentrating on the MOMPOD Trial for Metformin Plus Insulin Host: John Buse, MD, PhD Guest: Kim Boggess, MD The most common forms of diabetes encountered in pregnant patients include gestational diabetes and preexisting type 2 diabetes. So how does adding metformin to insulin treatment help these ... |
|
| 2024-04-09 |
Utilizing Hybrid Closed-Loop Technology for T1D Pediatric Patients Guest: R. Paul Wadwa, M.D. Since young kids have a different activity level and diet than older kids or adult patients, controlling type 1 diabetes in younger patients can be more challenging, and there tends to be more variability in their b... |
|
| 2024-04-09 |
Utilizing Hybrid Closed-Loop Technology for T1D Pediatric Patients Guest: R. Paul Wadwa, M.D. Since young kids have a different activity level and diet than older kids or adult patients, controlling type 1 diabetes in younger patients can be more challenging, and there tends to be more variability in their b... |
|
| 2024-04-08 |
Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients Host: Carol Wysham, MD Guest: A. Michael Lincoff, MD Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who ar... |
|
| 2024-04-08 |
Semaglutide Reduces CV Events in Non-Diabetic, Overweight Patients Host: Carol Wysham, MD Guest: A. Michael Lincoff, MD Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who ar... |
|
| 2024-03-27 | Host: John Buse, MD, PhD Guest: Louis J. Aronne, MD, FTOS In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive eith... |